Clinical Trials – Page 15

Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

7 months ago talkbio0Tagged Clinical Trials, Keytruda, Lynparza, ovarian neoplasm, Progression-Free Survival, Survival

Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival

Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017

7 months ago talkbio0Tagged Clinical Trials, Drug Development, MDD, Phase 3 trials, REL-1017, Relmada, Strategic Options, Unipolar Depression

Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development

AstraZeneca’s Calquence Combination Shows Promise in Chronic Lymphocytic Leukemia with Fixed-Duration Regimens

7 months ago talkbio0Tagged acalabrutinib, AMPLIFY, AstraZeneca, Calquence, Chronic Lymphocytic Leukemia, Clinical Trials, CLL, Fixed-Duration, obinutuzumab

AstraZeneca, Calquence, chronic lymphocytic leukemia, CLL, fixed-duration treatment, acalabrutinib, venetoclax, obinutuzumab, AMPLIFY trial

Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

7 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Nordisk, Obesity, semaglutide, Wegovy, Zepbound

Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk

Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

7 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, Immunomodulating Agents, Nuvig, NVG-2089, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Series B financing

Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.

Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer

7 months ago talkbio0Tagged BCG-Naïve, BCG-Unresponsive, Carcinoma of urinary bladder, invasive, Cell Therapy, Clinical Trials, Lyophilized Inactivated Group A Streptococcus TARA-002, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Phase 2, Protara Therapeutics

Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve

Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset

7 months ago talkbio0Tagged Clinical Trials, Congress (U.S. Legislature), ESMO, Head, Malignant Neoplasms, Merus, MRUS, N.V., Petosemtamab, Squamous cell carcinoma of the head and neck

Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024

Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile

7 months ago talkbio0Tagged Biclonics, Cancer of Neck, Clinical Trials, Congress (U.S. Legislature), Epidermal Growth Factor Receptor, ESMO, LGR5 gene, Merus, Petosemtamab

Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5

Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy

8 months ago talkbio0Tagged AMD, Attitude, Clinical Trials, Failure (biologic function), File (record), Glycogen storage disease type II, OTLK, Prices, United States Food and Drug Administration

Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing

Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations

8 months ago talkbio0Tagged amgen, Clinical Trials, MariTide, Obesity

Amgen, MariTide, weight loss, obesity treatment, clinical trial results